NCT05976763 2026-03-04
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
63 trialsNCT03150693 2026-03-02
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT01516580 2026-02-09
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06006117 2025-12-19
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT01650701 2025-09-25
RELEVANCE
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT04212013 2025-07-23
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT01303887 2025-04-18
PACIFICO
University of Liverpool
Phase 3 Completed
NCT01868269 2025-02-03
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Institut Curie
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT02950155 2024-10-26
Rinomax
Karolinska Institutet
Phase 3 Completed
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT03078855 2024-09-04
ILyAD
University of Rochester
Phase 3 Completed
NCT06573645 2024-08-27
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT00991211 2024-08-22
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Phase 3 Completed
NCT01456351 2024-08-22
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
University of Giessen
Phase 3 Completed
NCT06522555 2024-08-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
Phase 3 Recruiting
NCT06496308 2024-07-11
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital
Phase 3 Recruiting
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT00112931 2024-05-09
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
University College, London
Phase 3 Completed
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT05332587 2022-05-02
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT00992030 2021-08-19
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Fondazione Michelangelo
Phase 3 Terminated
NCT00052936 2021-05-18
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT02128061 2021-04-13
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00515554 2020-11-13
HD18 for Advanced Stages in Hodgkins Lymphoma
University of Cologne
Phase 3 Completed
NCT00513747 2020-04-22
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00137995 2019-08-28
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Completed
NCT00210353 2019-06-06
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 3 Completed
NCT00275054 2019-05-23
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT00003280 2019-05-15
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT00227695 2019-05-15
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT02767674 2019-01-03
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT00135499 2018-08-23
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Terminated
NCT00921414 2018-04-27
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
French Innovative Leukemia Organisation
Phase 3 Completed
NCT02858258 2017-12-19
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
European Mantle Cell Lymphoma Network
Phase 3 Recruiting
NCT00355199 2017-08-10
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Gruppo Italiano Terapie Innovative nei Linfomi
Phase 3 Completed
NCT00645606 2017-08-01
LLC2007SA
University Hospital, Tours
Phase 3 Completed
NCT03018626 2017-07-28
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT00140582 2017-03-13
Primary Rituximab and Maintenance
Lymphoma Study Association
Phase 3 Completed
NCT00140660 2017-03-13
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Terminated
NCT00209209 2017-03-07
MCLelderly
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT00841945 2017-02-23
Treatment of Aggressive Localized Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated